MA50034A - Composition de stimulation ovarienne contrôlée - Google Patents

Composition de stimulation ovarienne contrôlée

Info

Publication number
MA50034A
MA50034A MA050034A MA50034A MA50034A MA 50034 A MA50034 A MA 50034A MA 050034 A MA050034 A MA 050034A MA 50034 A MA50034 A MA 50034A MA 50034 A MA50034 A MA 50034A
Authority
MA
Morocco
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
stimulation
Prior art date
Application number
MA050034A
Other languages
English (en)
Other versions
MA50034B1 (fr
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA50034A publication Critical patent/MA50034A/fr
Publication of MA50034B1 publication Critical patent/MA50034B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA50034A 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée MA50034B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (fr) 2017-09-01 2018-08-31 Composition destinée à la stimulation ovarienne contrôlée

Publications (2)

Publication Number Publication Date
MA50034A true MA50034A (fr) 2021-05-12
MA50034B1 MA50034B1 (fr) 2022-02-28

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
MA50034A MA50034B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée
MA56224A MA56224B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA56224A MA56224B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Country Status (32)

Country Link
US (2) US11744879B2 (fr)
EP (3) EP3973982B1 (fr)
JP (2) JP6856819B2 (fr)
KR (2) KR20200045543A (fr)
CN (2) CN111050787A (fr)
AR (1) AR112541A1 (fr)
AU (1) AU2018326556B2 (fr)
BR (1) BR112020003379A2 (fr)
CA (1) CA3073624A1 (fr)
CL (1) CL2020000482A1 (fr)
DK (2) DK3973982T3 (fr)
EA (1) EA202090480A1 (fr)
ES (2) ES2904787T3 (fr)
FI (1) FI3973982T3 (fr)
HR (2) HRP20241171T1 (fr)
HU (2) HUE056726T2 (fr)
IL (1) IL272763B2 (fr)
JO (1) JOP20200034B1 (fr)
LT (2) LT3973982T (fr)
MA (2) MA50034B1 (fr)
MD (2) MD3675894T2 (fr)
MX (2) MX2020002235A (fr)
MY (1) MY200791A (fr)
PH (1) PH12020500404A1 (fr)
PL (2) PL3973982T3 (fr)
PT (2) PT3973982T (fr)
RS (2) RS65945B1 (fr)
SG (1) SG11202003840QA (fr)
SI (2) SI3973982T1 (fr)
TW (1) TWI749255B (fr)
UA (1) UA126869C2 (fr)
WO (1) WO2019043143A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250148B2 (fr) * 2000-01-27 2008-07-02 Laboratoires Serono SA Utilisation de fsh pour traiter l'infertilite
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ES2494928T3 (es) * 2007-09-21 2014-09-16 Pharmabrand S.A. Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
WO2011089602A2 (fr) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Dérivés d'aloé-émodine et leur utilisation pour le traitement du cancer
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
WO2012168680A1 (fr) 2011-06-06 2012-12-13 Ferring B.V. Préparation pharmaceutique
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino
EP3261661B1 (fr) 2015-02-26 2023-10-18 Ferring B.V. Menotropin pour le traitement de l'infertilité
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
RS61163B1 (sr) 2015-04-24 2021-01-29 Ferring Bv Postupak proizvodnje gonadotrofina
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
WO2019211153A1 (fr) 2018-04-30 2019-11-07 Ferring B.V. Composition destinée à la stimulation ovarienne contrôlée
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
AR112541A1 (es) 2019-11-06
EP3973982A1 (fr) 2022-03-30
PT3675894T (pt) 2022-01-25
US20240024424A1 (en) 2024-01-25
BR112020003379A2 (pt) 2020-08-25
JP7373479B2 (ja) 2023-11-02
DK3675894T3 (da) 2022-01-24
US20200197493A1 (en) 2020-06-25
AU2018326556B2 (en) 2024-09-26
HUE056726T2 (hu) 2022-03-28
PT3973982T (pt) 2024-09-16
JOP20200034A1 (ar) 2020-02-13
US12653864B2 (en) 2026-06-16
HUE068024T2 (hu) 2024-12-28
UA126869C2 (uk) 2023-02-15
JOP20200034B1 (ar) 2024-04-18
EP3973982B1 (fr) 2024-07-31
SG11202003840QA (en) 2020-05-28
HRP20211802T1 (hr) 2022-03-04
IL272763B1 (en) 2023-10-01
IL272763B2 (en) 2024-02-01
ES2904787T3 (es) 2022-04-06
EP3675894A1 (fr) 2020-07-08
MD3675894T2 (ro) 2022-03-31
MA56224B1 (fr) 2024-09-30
FI3973982T3 (fi) 2024-09-23
JP2021046398A (ja) 2021-03-25
LT3973982T (lt) 2024-09-10
CL2020000482A1 (es) 2020-06-26
CN111050787A (zh) 2020-04-21
ES2989511T3 (es) 2024-11-26
RS62810B1 (sr) 2022-02-28
WO2019043143A1 (fr) 2019-03-07
KR20250078595A (ko) 2025-06-02
EP4427806A2 (fr) 2024-09-11
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
PL3973982T3 (pl) 2024-11-04
MA56224A (fr) 2022-04-20
SI3675894T1 (sl) 2022-01-31
CN120617484A (zh) 2025-09-12
SI3973982T1 (sl) 2024-10-30
EP4427806A3 (fr) 2024-10-09
IL272763A (en) 2020-04-30
MA50034B1 (fr) 2022-02-28
RS65945B1 (sr) 2024-10-31
JP6856819B2 (ja) 2021-04-14
EA202090480A1 (ru) 2020-07-20
MX2024009224A (es) 2024-08-06
TW201919687A (zh) 2019-06-01
HRP20241171T1 (hr) 2024-11-22
TWI749255B (zh) 2021-12-11
MD3973982T2 (ro) 2024-11-30
US11744879B2 (en) 2023-09-05
MX2020002235A (es) 2020-07-20
AU2018326556A1 (en) 2020-03-05
JP2020528071A (ja) 2020-09-17
CA3073624A1 (fr) 2019-03-07
EP3675894B1 (fr) 2021-11-03
PH12020500404A1 (en) 2021-03-01
KR20200045543A (ko) 2020-05-04
DK3973982T3 (da) 2024-09-23
MY200791A (en) 2024-01-16

Similar Documents

Publication Publication Date Title
IL272888A (en) Uses of piperidinyl-indole derivatives
EP3443998C0 (fr) Adaptation des valeurs d'insuline
EP3436867A4 (fr) Suivi de visiocasque
EP3732239A4 (fr) Composition de polyéthylène
IL272851A (en) Methods of using dipivefrin
PT3645518T (pt) Síntese de omecamtiv mecarbil
EP3388052A4 (fr) Composition fonctionnelle de modification de surface
PT3457851T (pt) Derivados de sobetiroma
IL268731A (en) New uses of anti-sirpg antibodies
EP3688095A4 (fr) Composition de polycarbonate
EP3602901C0 (fr) Structure pucch de numérologie mixte
DK3787667T3 (da) Sammensætning til kontrolleret ovariestimulation
EP3674359A4 (fr) Composition de latex
EP3310794A4 (fr) Synthèse et application de composés de formation de microbulles
GB2555968B (en) Controlled activation of extended-life cement compositions
EP3590033A4 (fr) Fourniture de contenu
IL272670A (en) Preparation of micro-electrodes
HRP20251697T1 (hr) Kristalni oblik n-butildeoksigalaktonojirimicina
IL272763A (en) The composition for controlled stimulation of the ovary
EP3513304A4 (fr) Fourniture de contenus recommandés
EP3548433C0 (fr) Composition d'atomes boranes artificiels picocristallins
EP3473373A4 (fr) Composition de brasure
MA53909A (fr) Compositions et méthodes de stimulation ovarienne contrôlée
PL3350308T3 (pl) Zastosowanie włókna liocelowego
EP3515442A4 (fr) Réglage de dose